MX2023001335A - Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma. - Google Patents
Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma.Info
- Publication number
- MX2023001335A MX2023001335A MX2023001335A MX2023001335A MX2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- inhibitor
- combination
- pharmaceutical compositions
- hypomethylating agent
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 3
- 229940075628 hypomethylating agent Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 abstract 1
- 229960002756 azacitidine Drugs 0.000 abstract 1
- 229960003603 decitabine Drugs 0.000 abstract 1
- 229950001546 guadecitabine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una combinación que comprende un inhibidor de Bcl-2 con un agente hipometilante, usos en el tratamiento de cánceres y composiciones farmacéuticas de la misma. El inhibidor de Bcl-2 es 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroisoquinolin -2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirrol-3-il)- N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida y el agente hipometilante se selecciona de decitabina, azacitidina y guadecitabina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059419P | 2020-07-31 | 2020-07-31 | |
| EP20195633 | 2020-09-11 | ||
| PCT/EP2021/071368 WO2022023514A1 (en) | 2020-07-31 | 2021-07-30 | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001335A true MX2023001335A (es) | 2023-04-27 |
Family
ID=77595496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001335A MX2023001335A (es) | 2020-07-31 | 2021-07-30 | Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230270748A1 (es) |
| EP (1) | EP4188387A1 (es) |
| JP (1) | JP2023537290A (es) |
| KR (1) | KR20230044452A (es) |
| CN (1) | CN116390735A (es) |
| AU (1) | AU2021316674A1 (es) |
| BR (1) | BR112023001307A2 (es) |
| CA (1) | CA3190276A1 (es) |
| CL (1) | CL2023000242A1 (es) |
| CR (1) | CR20230046A (es) |
| IL (1) | IL300145A (es) |
| MX (1) | MX2023001335A (es) |
| WO (1) | WO2022023514A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UY38431A (es) | 2018-10-31 | 2020-05-29 | Servier Lab | Formulación basada en ciclodextrina de un inhibidor de bcl-2 |
| PE20211503A1 (es) | 2018-10-31 | 2021-08-11 | Servier Lab | Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, metodo para preparar la misma y composiciones farmaceuticas que contienen la misma |
-
2021
- 2021-07-30 CN CN202180066875.XA patent/CN116390735A/zh active Pending
- 2021-07-30 MX MX2023001335A patent/MX2023001335A/es unknown
- 2021-07-30 KR KR1020237006112A patent/KR20230044452A/ko unknown
- 2021-07-30 JP JP2023505990A patent/JP2023537290A/ja active Pending
- 2021-07-30 CA CA3190276A patent/CA3190276A1/en active Pending
- 2021-07-30 WO PCT/EP2021/071368 patent/WO2022023514A1/en active Application Filing
- 2021-07-30 CR CR20230046A patent/CR20230046A/es unknown
- 2021-07-30 BR BR112023001307A patent/BR112023001307A2/pt unknown
- 2021-07-30 US US18/007,321 patent/US20230270748A1/en active Pending
- 2021-07-30 IL IL300145A patent/IL300145A/en unknown
- 2021-07-30 EP EP21763238.9A patent/EP4188387A1/en active Pending
- 2021-07-30 AU AU2021316674A patent/AU2021316674A1/en active Pending
-
2023
- 2023-01-25 CL CL2023000242A patent/CL2023000242A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022023514A1 (en) | 2022-02-03 |
| CN116390735A (zh) | 2023-07-04 |
| US20230270748A1 (en) | 2023-08-31 |
| CA3190276A1 (en) | 2022-02-03 |
| EP4188387A1 (en) | 2023-06-07 |
| JP2023537290A (ja) | 2023-08-31 |
| CR20230046A (es) | 2023-04-11 |
| AU2021316674A1 (en) | 2023-03-02 |
| CL2023000242A1 (es) | 2023-11-10 |
| IL300145A (en) | 2023-03-01 |
| BR112023001307A2 (pt) | 2023-02-14 |
| KR20230044452A (ko) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuhlen et al. | Molecular approaches to treating pediatric leukemias | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| NZ588913A (en) | Liver cancer drug | |
| CL2008002224A1 (es) | Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer. | |
| TW200642684A (en) | Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes | |
| BRPI0510269B8 (pt) | composições de dalbavancina para o tratamento de infecções bacterianas | |
| Hurtubise et al. | Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells | |
| GEP20237580B (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| SG160323A1 (en) | Methods for controlling angiogenesis and cell proliferation | |
| FR2869540B1 (fr) | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| MX2023001335A (es) | Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma. | |
| RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
| IL285628A (en) | A pharmaceutical preparation containing a flt3 inhibitor and a hypomethylating agent for the treatment of acute myeloid leukemia | |
| ECSP003756A (es) | Mezcla de linezoild y otros agentes antibacterianos | |
| UA92592C2 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent such as taxane for the treatment of cancer | |
| Davies et al. | Antisense oligonucleotides in the treatment of non–small-cell lung cancer | |
| CR20230308A (es) | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 | |
| AR027677A1 (es) | Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer | |
| Eliasen et al. | Chemotherapy-induced nausea and vomiting in children–the missing evidence | |
| TR200400812T3 (tr) | KanserÁtedavisiÁiçinÁretinoidÁreseptörÁligandlarınınÁveÁseçilenÁsitotoksikÁmaddelerinÁsinerjistikÁkombinasyonları | |
| UA90658C2 (ru) | Композиция антагониста vegf и антипролиферативного средства | |
| MX2019014166A (es) | Composicion farmaceutica de caseinato de sodio y antineoplasicos para el tratamiento de cancer. | |
| AR118924A1 (es) | Inhibidores de bcl-2 para uso en el tratamiento de un cáncer mediado por bcl-2 que porta la mutación gly101val | |
| Rochford et al. | Metronomic Therapy for HIV-Associated Malignancies |